Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Follow-Up Questions
Who is the CEO of Evoke Pharma Inc?
Mr. Matthew D'Onofrio is the President of Evoke Pharma Inc, joining the firm since 2007.
What is the price performance of EVOK stock?
The current price of EVOK is $5.11, it has increased 0.59% in the last trading day.
What are the primary business themes or industries for Evoke Pharma Inc?
Evoke Pharma Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Evoke Pharma Inc market cap?
Evoke Pharma Inc's current market cap is $7.9M
Is Evoke Pharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Evoke Pharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
